B-cell non-Hodgkin lymphoma

Summary

B-cell non-Hodgkin lymphoma (MONDO:0015759) is a cancer (an umbrella term covering 5 Mondo subtypes) with 2 cohort genes (2 CIViC-evidence somatic drivers; 1 ClinVar predisposition record) and 434 clinical trials. Molecularly, EZH2 Y646S OR EZH2 Y646F OR EZH2 Y646H OR EZH2 Y646C OR EZH2 Y646N OR EZH2 A692V OR EZH2 A682G confers sensitivity to Tazemetostat in B-cell Non-Hodgkin Lymphoma (CIViC Level A); 3 further subtype–drug associations are mapped below. Top therapeutic interventions include rituximab, glofitamab, and mosunetuzumab.

At a glance

• Classification: Cancer
• Prevalence: 1-5 / 10 000 (Europe) [Orphanet-validated]
• Umbrella term: 5 Mondo subtypes
• Cohort genes: 2
• ClinVar variants: 1
• Clinical trials: 434
• Precision-medicine evidence (CIViC): 4 subtype–drug associations

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	1-5 / 10 000	17.45	Europe	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	B-cell non-Hodgkin lymphoma
Mondo ID	MONDO:0015759
EFO	EFO:1001938
Orphanet	171915
NCIT	C3457
GARD	0020132
Is cancer (heuristic)	yes

Also known as: B-cell lymphoma · B-cell NHL · B-cell non Hodgkin’s lymphoma · B-cell non-Hodgkin lymphoma · B-cell non-Hodgkin’s lymphoma · lymphomas non-Hodgkin’s B-cell · non-Hodgkin’s B-cell lymphoma · non-Hodgkin’s lymphoma B-cell

Data availability: 1 ClinVar variant · 42 cell lines.

Disease family

An umbrella term covering 5 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › immune system disorder › leukocyte disorder › B-cell neoplasm › B-cell non-Hodgkin lymphoma

Related subtypes (4): lymphoplasmacytic lymphoma, neoplasm of mature B-cells, high-grade B-cell lymphoma double-hit/triple-hit, large B-cell lymphoma

Subtypes (5): B-cell acute lymphoblastic leukemia, indolent B-cell non-Hodgkin lymphoma, aggressive B-cell non-Hodgkin lymphoma, plasma cell leukemia, central nervous system non-hodgkin lymphoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

1 retrieved; paginated sample, class counts are floors:

1 benign

ClinVar	Variant (HGVS)	Gene	Classification	Review
3027	NM_000051.4(ATM):c.3118A>G (p.Met1040Val)	ATM	Benign	reviewed by expert panel

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 9 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

Gene	intOGen role	Cancer types	CIViC
EZH2	Act	ALL,AML,DLBCLNOS,ES,MLYM,NHL	CIViC #63
ATM	LoF	BLCA,BRCA,CCRCC,CHOL,CLLSLL,COAD,COADREAD,ESCA,HCC,LUAD,LUSC,MEL,NSCLC,PAAD,PANCREAS,PANET,PCM,PLMESO,PRAD,PROSTATE,STAD,UCEC,UTUC,WDTC	CIViC #69

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
EZH2	Orphanet:3447	Weaver syndrome
ATM	Orphanet:100	Ataxia-telangiectasia
ATM	Orphanet:1331	Familial prostate cancer
ATM	Orphanet:145	Hereditary breast and/or ovarian cancer syndrome
ATM	Orphanet:227535	Hereditary breast cancer
ATM	Orphanet:370109	Ataxia-telangiectasia variant
ATM	Orphanet:440437	Familial colorectal cancer Type X
ATM	Orphanet:52416	Mantle cell lymphoma
ATM	Orphanet:67038	B-cell chronic lymphocytic leukemia

Cohort genes → proteins

2 cohort genes, 2 distinct canonical proteins.

Evidence partition

Subset	Genes
civic_only	1
multi_evidence	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
EZH2	HGNC:3527	ENSG00000106462	Q15910	Histone-lysine N-methyltransferase EZH2	civic_evidence
ATM	HGNC:795	ENSG00000149311	Q13315	Serine-protein kinase ATM	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
EZH2	Histone-lysine N-methyltransferase EZH2	Catalytic subunit of the PRC2/EED-EZH2 complex, a Polycomb group (PcG) complex that methylates ‘Lys-9’ (H3K9me) and ‘Lys-27’ (H3K27me) of histone H3, leading to transcriptional repression of the affected target gene.
ATM	Serine-protein kinase ATM	Serine/threonine protein kinase which activates checkpoint signaling upon double strand breaks (DSBs), apoptosis and genotoxic stresses such as ionizing ultraviolet A light (UVA), thereby acting as a DNA damage sensor.

Protein-family classification

Druggable: 2 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Kinase	1	13.9×	0.142
Enzyme (other)	1	6.0×	0.160

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
EZH2	Enzyme (other)	yes	2.1.1.356	SANT/Myb, SET_dom, EZH1/EZH2_N
ATM	Kinase	yes	2.7.11.1	PI3/4_kinase_cat_dom, PIK-rel_kinase_FAT, FATC_dom

Expression context

Cohort genes with no expression data: 0.

2 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	2
unknown	0

Top tissues across cohort

Tissue	Cohort genes
embryo	1
ganglionic eminence	1
ventricular zone	1
calcaneal tendon	1
colonic epithelium	1
corpus callosum	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
EZH2	216	ubiquitous	marker	ganglionic eminence, ventricular zone, embryo
ATM	286	ubiquitous	marker	calcaneal tendon, colonic epithelium, corpus callosum

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
EZH2	9,646
ATM	7,383

Structural data

PDB: 2 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
EZH2	Q15910	38
ATM	Q13315	14

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 71. Enrichment computed across 2 evidence-associated genes (2 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Sensing of DNA Double Strand Breaks	1	951.7×	0.015	ATM
TP53 Regulates Transcription of Caspase Activators and Caspases	1	475.8×	0.015	ATM
Pexophagy	1	475.8×	0.015	ATM
Defective homologous recombination repair (HRR) due to PALB2 loss of function	1	475.8×	0.015	ATM
Diseases of DNA Double-Strand Break Repair	1	407.9×	0.015	ATM
Defective homologous recombination repair (HRR) due to BRCA2 loss of function	1	407.9×	0.015	ATM
Stabilization of p53	1	380.7×	0.015	ATM
p53-Dependent G1 DNA Damage Response	1	356.9×	0.015	ATM
p53-Dependent G1/S DNA damage checkpoint	1	356.9×	0.015	ATM
G1/S DNA Damage Checkpoints	1	335.9×	0.015	ATM
Resolution of D-Loop Structures	1	317.2×	0.015	ATM
Diseases of DNA repair	1	285.5×	0.015	ATM
TP53 Regulates Transcription of Cell Death Genes	1	271.9×	0.015	ATM
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release	1	271.9×	0.015	ATM
Regulation of TP53 Activity through Methylation	1	271.9×	0.015	ATM
Regulation of TP53 Expression and Degradation	1	259.6×	0.015	ATM
DNA Double Strand Break Response	1	237.9×	0.015	ATM
Impaired BRCA2 binding to PALB2	1	228.4×	0.015	ATM
Defective homologous recombination repair (HRR) due to BRCA1 loss of function	1	211.5×	0.015	ATM
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function	1	211.5×	0.015	ATM
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function	1	211.5×	0.015	ATM
Cellular response to heat stress	1	196.9×	0.015	ATM
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)	1	196.9×	0.015	ATM
Homologous DNA Pairing and Strand Exchange	1	190.3×	0.015	ATM
Homology Directed Repair	1	154.3×	0.015	ATM
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA)	1	154.3×	0.015	ATM
Impaired BRCA2 binding to RAD51	1	154.3×	0.015	ATM
Resolution of D-loop Structures through Holliday Junction Intermediates	1	150.3×	0.015	ATM
HDR through Single Strand Annealing (SSA)	1	146.4×	0.015	ATM
Regulation of TP53 Degradation	1	146.4×	0.015	ATM

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
hepatocyte homeostasis	1	4213.0×	0.005	EZH2
establishment of RNA localization to telomere	1	4213.0×	0.005	ATM
establishment of protein-containing complex localization to telomere	1	4213.0×	0.005	ATM
positive regulation of telomerase catalytic core complex assembly	1	4213.0×	0.005	ATM
pre-B cell allelic exclusion	1	2808.7×	0.005	ATM
regulation of gliogenesis	1	2808.7×	0.005	EZH2
cellular response to trichostatin A	1	2808.7×	0.005	EZH2
cellular response to nitrosative stress	1	2808.7×	0.005	ATM
negative regulation of striated muscle cell differentiation	1	2106.5×	0.005	EZH2
regulation of kidney development	1	2106.5×	0.005	EZH2
response to tetrachloromethane	1	2106.5×	0.005	EZH2
positive regulation of cell migration	2	61.7×	0.005	EZH2, ATM
peptidyl-serine autophosphorylation	1	1685.2×	0.005	ATM
negative regulation of telomere capping	1	1685.2×	0.005	ATM
skeletal muscle satellite cell maintenance involved in skeletal muscle regeneration	1	1404.3×	0.005	EZH2
regulation of telomere maintenance via telomerase	1	1404.3×	0.005	ATM
positive regulation of telomere maintenance via telomere lengthening	1	1404.3×	0.005	ATM
lipoprotein catabolic process	1	1203.7×	0.005	ATM
cerebellar cortex development	1	1053.2×	0.005	EZH2
V(D)J recombination	1	1053.2×	0.005	ATM
facultative heterochromatin formation	1	1053.2×	0.005	EZH2
regulatory ncRNA-mediated heterochromatin formation	1	936.2×	0.005	EZH2
meiotic telomere clustering	1	936.2×	0.005	ATM
female meiotic nuclear division	1	842.6×	0.005	ATM
negative regulation of keratinocyte differentiation	1	842.6×	0.005	EZH2
histone mRNA catabolic process	1	842.6×	0.005	ATM
cellular response to X-ray	1	842.6×	0.005	ATM
DNA double-strand break processing	1	766.0×	0.005	ATM
subtelomeric heterochromatin formation	1	766.0×	0.005	EZH2
negative regulation of retinoic acid receptor signaling pathway	1	766.0×	0.005	EZH2

Therapeutics

Drugs indicated for this disease

2 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Loncastuximab Tesirine	Approved (phase 4)
Polatuzumab Vedotin	Approved (phase 4)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Carboplatin, Ifosfamide, Prednisone, Rituximab, Tucidinostat.

Drug target analysis

Approved (phase 4): 2 · Phase ≥3: 2 · Phased (≥1): 2 · Undrugged: 0

Druggability breadth: 2 of 2 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
EZH2	TAZEMETOSTAT
ATM	AMIODARONE HYDROCHLORIDE

Top cohort targets by molecule count

Symbol	Molecules	Max phase
ATM	35	4
EZH2	6	4

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
TAZEMETOSTAT	4	EZH2
AMIODARONE HYDROCHLORIDE	4	ATM
FURAZOLIDONE	4	ATM
ESTRADIOL ACETATE	4	ATM
NAFTIFINE HYDROCHLORIDE	4	ATM
METHYSERGIDE MALEATE	4	ATM
AMITRIPTYLINE HYDROCHLORIDE	4	ATM
XYLOMETAZOLINE HYDROCHLORIDE	4	ATM
FLUVOXAMINE MALEATE	4	ATM
ESTRADIOL VALERATE	4	ATM
PERMETHRIN	4	ATM
MITOTANE	4	ATM
TICLOPIDINE HYDROCHLORIDE	4	ATM
ENOXIMONE	4	ATM
METHYLENE BLUE ANHYDROUS	4	ATM
DITHIAZANINE IODIDE	4	ATM
ETHACRYNIC ACID	4	ATM
SECNIDAZOLE	4	ATM
MENADIONE	4	ATM
FENOFIBRATE	4	ATM
DIPYRIDAMOLE	4	ATM
DACTOLISIB	3	ATM
MEVROMETOSTAT	2	EZH2
VALEMETOSTAT	2	EZH2
ZEPRUMETOSTAT	2	EZH2
STREPTONIGRIN	2	ATM
CALCIMYCIN	2	ATM
ENPIROLINE	2	ATM
OXACEPROL	2	ATM
TOLONIUM CHLORIDE	2	ATM

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 2.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
EZH2	839	Binding:833, Functional:6
ATM	240	Binding:233, Functional:5, ADMET:2

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
EZH2	2.1.1.356	[histone H3]-lysine27 N-trimethyltransferase
ATM	2.7.11.1	non-specific serine/threonine protein kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
EZH2	839
ATM	240

Pharmacogenomics

Cohort genes with a PharmGKB record: 2; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

29 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Compound	Max phase	Cohort target (bioactivity)
AMIODARONE HYDROCHLORIDE	4	ATM
FURAZOLIDONE	4	ATM
ESTRADIOL ACETATE	4	ATM
NAFTIFINE HYDROCHLORIDE	4	ATM
METHYSERGIDE MALEATE	4	ATM
AMITRIPTYLINE HYDROCHLORIDE	4	ATM
XYLOMETAZOLINE HYDROCHLORIDE	4	ATM
FLUVOXAMINE MALEATE	4	ATM
ESTRADIOL VALERATE	4	ATM
PERMETHRIN	4	ATM
MITOTANE	4	ATM
TICLOPIDINE HYDROCHLORIDE	4	ATM
ENOXIMONE	4	ATM
METHYLENE BLUE ANHYDROUS	4	ATM
DITHIAZANINE IODIDE	4	ATM
ETHACRYNIC ACID	4	ATM
SECNIDAZOLE	4	ATM
MENADIONE	4	ATM
FENOFIBRATE	4	ATM
DIPYRIDAMOLE	4	ATM
DACTOLISIB	3	ATM
MEVROMETOSTAT	2	EZH2
VALEMETOSTAT	2	EZH2
ZEPRUMETOSTAT	2	EZH2
STREPTONIGRIN	2	ATM
CALCIMYCIN	2	ATM
ENPIROLINE	2	ATM
OXACEPROL	2	ATM
TOLONIUM CHLORIDE	2	ATM

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	2	EZH2, ATM
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Clinical trials & evidence

Clinical trials

Clinical trials: 434.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	181
PHASE2	88
PHASE1/PHASE2	87
Not specified	42
EARLY_PHASE1	22
PHASE3	10
PHASE4	2
PHASE2/PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06956092	PHASE4	NOT_YET_RECRUITING	Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
NCT07270835	PHASE4	RECRUITING	Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma
NCT05991388	PHASE2/PHASE3	RECRUITING	A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
NCT06230224	PHASE3	ACTIVE_NOT_RECRUITING	A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma
NCT06742996	PHASE3	RECRUITING	A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
NCT07516093	PHASE3	NOT_YET_RECRUITING	Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
NCT00162656	PHASE3	COMPLETED	Treatment of Mature B-cell Lymphoma/Leukaemia
NCT00486759	PHASE3	TERMINATED	A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma
NCT00841945	PHASE3	TERMINATED	Treatment of Aggressive Localized Lymphoma
NCT01516580	PHASE3	COMPLETED	Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients
NCT02787239	PHASE3	COMPLETED	Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL
NCT02910063	PHASE2/PHASE3	COMPLETED	Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL
NCT04539119	PHASE3	UNKNOWN	Entecavir and Tenofovir Versus Entecavir in Lymphoma Patients With Positive HBV DNA
NCT05164770	PHASE3	UNKNOWN	Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma
NCT02628405	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma
NCT03038672	PHASE2	ACTIVE_NOT_RECRUITING	Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
NCT03114865	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
NCT03147885	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma
NCT03277729	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
NCT03478514	PHASE2	ACTIVE_NOT_RECRUITING	Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma
NCT03505762	PHASE2	ACTIVE_NOT_RECRUITING	Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment
NCT03671018	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
NCT03888105	PHASE2	ACTIVE_NOT_RECRUITING	A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
NCT03995147	PHASE2	ACTIVE_NOT_RECRUITING	Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma
NCT04148430	PHASE2	ACTIVE_NOT_RECRUITING	A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy
NCT04257578	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma
NCT04491370	PHASE1/PHASE2	RECRUITING	Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
NCT04531046	PHASE2	ACTIVE_NOT_RECRUITING	Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation
NCT04544592	PHASE1/PHASE2	RECRUITING	UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
NCT04792502	PHASE2	RECRUITING	Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
NCT05091541	PHASE1/PHASE2	NOT_YET_RECRUITING	A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma
NCT05092451	PHASE1/PHASE2	RECRUITING	Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
NCT05201248	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
NCT05281809	PHASE2	RECRUITING	Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
NCT05338931	PHASE1/PHASE2	RECRUITING	Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin’s Lymphoma
NCT05436223	PHASE2	RECRUITING	Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin’s Lymphoma
NCT05442515	PHASE1/PHASE2	RECRUITING	CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
NCT05453396	PHASE2	RECRUITING	Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
NCT05507541	PHASE2	ACTIVE_NOT_RECRUITING	TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT05583149	PHASE2	ACTIVE_NOT_RECRUITING	Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
RITUXIMAB	4	55
GLOFITAMAB	4	8
MOSUNETUZUMAB	4	8
POLATUZUMAB VEDOTIN	4	7
UBLITUXIMAB	4	5
AXICABTAGENE CILOLEUCEL	4	4
EPCORITAMAB	4	4
IBRUTINIB	4	4
LONCASTUXIMAB TESIRINE	4	4
PIRTOBRUTINIB	4	4
TOCILIZUMAB	4	4
ZANUBRUTINIB	4	4
ENTECAVIR ANHYDROUS	4	3
ETOPOSIDE PHOSPHATE	4	3
IDELALISIB	4	3
INOTUZUMAB OZOGAMICIN	4	3
TAZEMETOSTAT	4	3
2-MERCAPTOETHANESULFONIC ACID	4	2
ACALABRUTINIB	4	2
ANAKINRA	4	2
BLINATUMOMAB	4	2
DOXORUBICIN	4	2
IFOSFAMIDE	4	2
PENTOSTATIN	4	2
SELINEXOR	4	2
TAFASITAMAB	4	2
TISAGENLECLEUCEL	4	2
VINCRISTINE	4	2
VORINOSTAT	4	2
YTTRIUM Y 90 IBRITUMOMAB TIUXETAN	4	2

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 4 predictive associations from 4 curated evidence items; also 2 oncogenic.

Molecular subtype	Therapy	Effect	Level	CIViC
EZH2 Y646S OR EZH2 Y646F OR EZH2 Y646H OR EZH2 Y646C OR EZH2 Y646N OR EZH2 A692V OR EZH2 A682G	Tazemetostat	Sensitivity/Response	CIViC A	EID11220
CD80 Overexpression	Cisplatin + Galiximab	Sensitivity/Response	CIViC D	EID12554
EZH2 Y646F	Tazemetostat	Sensitivity/Response	CIViC D	EID10999
EZH2 Y646F	JQEZ5	Sensitivity/Response	CIViC D	EID11083